Full-Time

Executive Administrator

Posted on 11/4/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$81.8k - $106.8k/yr

+ Annual Bonus Program + Discretionary Profit Sharing + 401K with company match + LTI + Pet Insurance + Tuition Assistance + Employee Referral Awards

La Jolla, San Diego, CA, USA

In Person

Category
Administrative & Executive Assistance (3)
, ,
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • B.S. or M.S. degree in Business Administration, Management or closely related discipline required.
  • Minimum six (6) years’ experience supporting high level executives, preferably in the life sciences industry.
  • Advanced proficiency with Microsoft Office Suite (MS Word, MS Excel, and MS PowerPoint).
  • Advanced proficiency with project management software, e.g. MS Project
  • Ability to prioritize tasks effectively, manage multiple deadlines, and adapt to changing priorities in a fast-paced environment.
  • Discretion in handling confidential/proprietary information.
  • Normal office environment with prolonged sitting and extensive computer work.
  • Requires up to 5% domestic travel.
Responsibilities
  • Provide comprehensive administrative support to the CSO and GRO ELT members ensuring seamless operations and efficient workflow.
  • Facilitate CSO's and ELT members’ travel arrangements, including domestic and international travel, by adhering to travel policies and procedures, organizing itineraries, monitoring expenses, and managing important deadlines.
  • Plan and coordinate meetings, both on-site and off-site, involving staff members, by scheduling meetings, reserving conference rooms, preparing and distributing meeting materials, coordinating audio-visual equipment and catering needs, as well as formatting documents into final form.
  • Manage CSO's calendar, proactively bringing attention to crucial matters and ensuring timely responses to emails and other communications.
  • Draft, proofread, and format documents, maintaining a high standard of accuracy and professionalism.
  • Generate, edit and format presentations for the CSO to be used in internal and externals meetings
  • Attend meetings as required, preparing and maintaining detailed meeting notes to capture key discussions and action items.
  • Effectively manage documents across various software programs, demonstrating proficiency with different technologies and a willingness to adapt and learn new tools as necessary.
  • Act as first point of contact for internal and external communications addressed to the CSO. Handle general inquiries via telephone and email for the department(s), addressing routine and non-routine questions promptly and identifying urgent activities for timely resolution.
  • Manages incoming telephone calls, correspondence, and general inquiries, ensuring questions are addressed or routed to the appropriate staff member.
  • Support GRO projects, including those of high complexity.
  • Coordinate various project activities, offering guidance across different areas such as needs assessment and prioritization, ensuring alignment with project objectives and timelines.
  • Support the CSO to develop multi-year planning strategies and tactics aimed at ensuring the project's long-term success.
  • Maintain regular communication with the CSO, provide updates on task statuses and discuss priorities and other pertinent matters.
  • Execute project directives by liaising with multiple departments, including interfacing with other KKNA & KKC functional groups, outside partners and other stakeholders, to foster relationships and facilitate effective communication and issue resolution.
  • Serve as a representative of the project and the CSO in technical and administrative capacities at external events such as meetings, conferences, and vendor engagements as required.
  • Other duties as assigned.
Desired Qualifications
  • Project Management Professional (PMP) certification.
  • Experience supporting a global leader is a plus.
  • Familiarity with Japanese work culture is a plus.

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE